Parikh is backed up by experienced CRO leader William Gannon Jr., M.D., who is LyfeSci’s chief medical officer. Gannon has ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA ...

Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. | Sanofi’s $1.7 billion rare disease bet ...

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

Boston Scientific’s third-quarter revenue topped $5 billion, up 20.3% year over year. Growth eased slightly from the second ...

Following three years of internal development, Expedition Medicines is taking flight. The company is supported by a $50 ...

Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) ...

Thermo Fisher Scientific’s plan for growth is paying off as the biopharma service provider and supplier posted a sales bump ...

In one of the biggest healthcare acquisitions of its kind this year, medtech diagnostics specialist Hologic will go private ...

Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the ...

Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and ...